Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: di tanna gl. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.
Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S. Wang N, et al. Among authors: di tanna gl. Lancet Diabetes Endocrinol. 2020 Jan;8(1):36-49. doi: 10.1016/S2213-8587(19)30388-2. Lancet Diabetes Endocrinol. 2020. PMID: 31862150
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Jardine MJ, et al. Among authors: di tanna gl. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168. J Am Soc Nephrol. 2020. PMID: 32354987 Free PMC article. Clinical Trial.
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
van der Aart-van der Beek AB, Cherney D, Laverman GD, Stefansson B, van Raalte DH, Hoogenberg K, Reyner D, Li Q, Di Tanna GL, Greasley PJ, Heerspink HJL. van der Aart-van der Beek AB, et al. Among authors: di tanna gl. Diabetes Obes Metab. 2021 Aug;23(8):1961-1967. doi: 10.1111/dom.14411. Epub 2021 May 14. Diabetes Obes Metab. 2021. PMID: 33908683 Free PMC article.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Heerspink HJL, Oshima M, Zhang H, Li J, Agarwal R, Capuano G, Charytan DM, Craig J, de Zeeuw D, Di Tanna GL, Levin A, Neal B, Perkovic V, Wheeler DC, Yavin Y, Jardine MJ. Heerspink HJL, et al. Among authors: di tanna gl. Am J Kidney Dis. 2022 Feb;79(2):244-256.e1. doi: 10.1053/j.ajkd.2021.05.005. Epub 2021 May 23. Am J Kidney Dis. 2022. PMID: 34029680 Clinical Trial.
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B. Liao J, et al. Among authors: di tanna gl. Diabetes Metab. 2022 Jul;48(4):101331. doi: 10.1016/j.diabet.2022.101331. Epub 2022 Feb 13. Diabetes Metab. 2022. PMID: 35172198 Clinical Trial.
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.
Young TK, Toussaint ND, Di Tanna GL, Arnott C, Hockham C, Kang A, Schutte AE, Perkovic V, Mahaffey KW, Agarwal R, Bakris GL, Charytan DM, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Zhang H, Jardine MJ. Young TK, et al. Among authors: di tanna gl. J Diabetes Res. 2022 May 27;2022:9998891. doi: 10.1155/2022/9998891. eCollection 2022. J Diabetes Res. 2022. PMID: 35677742 Free PMC article.
Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD.
Martin A, Hancox RJ, Chang CL, Beasley R, Wrobel J, McDonald V, Dobler CC, Yang IA, Farah CS, Cochrane B, Hillis GS, Scowcroft CP, Aggarwal A, Di Tanna GL, Balicki G, Galgey S, Jenkins C. Martin A, et al. Among authors: di tanna gl. BMJ Open. 2021 Aug 27;11(8):e053446. doi: 10.1136/bmjopen-2021-053446. BMJ Open. 2021. PMID: 34452971 Free PMC article.
Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial.
Kotwal S, Cass A, Coggan S, Gray NA, Jan S, McDonald S, Polkinghorne KR, Rogers K, Talaulikar G, Di Tanna GL, Gallagher M; REDUCCTION Investigators. Kotwal S, et al. Among authors: di tanna gl. BMJ. 2022 Apr 12;377:e069634. doi: 10.1136/bmj-2021-069634. BMJ. 2022. PMID: 35414532 Free PMC article. Clinical Trial.
178 results